BGM0504

Phase 3Small molecule

BBrightGene Bio-Medical Technology Co., Ltd.

BGM0504 is one of 95 small molecule programs targeting Weight loss. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossActive, not recruiting

Type 2 DiabetesActive, not recruiting

ObesityActive, not recruiting

Overweight or ObeseNot yet recruiting

Weight LossPhase 2

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Overweight or ObesePhase 2

Not yet recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

BGM0504

BBrightGene Bio-Medical Technology Co., Ltd.

Phase 3

2 2

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 3

Aurlumyn

BBTG International Inc.

Preclinical

1 4

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 5

Forxiga

AstraZeneca

Preclinical

3 6

Sulfonylureas

Eli Lilly

Preclinical

1 7

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 8

GLP-1

RRigshospitalet, Denmark

Preclinical

1 9

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 10

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Type 2 Diabetes

NCT07064486

Q1 2027

Phase 2Not yet recruiting

Overweight or Obese

NCT07658560

Clinical

Trials by Indication[1]

Overweight4 trials

A Study of BGM0504 in Overweight or Obese Participants

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT06920056·28 enrolled

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT07239973·75 enrolled

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Recruiting·BBrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.·Phase 3·NCT06704581·620 enrolled

Show 1 more trial

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT07166081·80 enrolled

Type 2 Diabetes2 trials

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 3·NCT07064486·477 enrolled

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06974825·67 enrolled

Weight loss1 trial

A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06973681·120 enrolled

Impaired Renal Function1 trial

A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT06929156·34 enrolled

Obesity1 trial

A Study of BGM0504 in Participants With Obesity

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06911203·90 enrolled

2 more indications

Overweight or Obese1 trial

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes

Not yet recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT07658560·200 enrolled

Unspecified1 trial

Bioequivalence Study of BGM0504 Injection

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT07382908·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for BGM0504. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGM0504 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGM0504. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BrightGene Bio-Medical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBrightGene Bio-Medical Technology Co., Ltd.

BGM0504

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Trials by Indication[1]

Overweight4 trials

Type 2 Diabetes2 trials

Weight loss1 trial

Impaired Renal Function1 trial

Obesity1 trial

Overweight or Obese1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News